Practice – Pre-trial or post-judgment relief. The Chancery Division, among other things, made an order for unlimited standard disclosure by the defendant pharmaceutical companies in respect of certain claims brought against them by the United Kingdom health authorities for damages for alleged breaches of competition law. However, it held that it was not appropriate to order enhanced disclosure at the present stage in relation to the defendants' application for the relevant patent and submissions to regulatory authorities.